eli lilly glp-1 advantage decreasing Some US employers to drop coverage of obesity drugs in 2027 as use increases 🧬 Eli Lilly ($LLY): The

There is also an ongoing cardiovascular outcomes trial of tirzepatide (SURPASS-CVOT) in individuals with type 2 diabetes and cardiovascular disease [91], which, if successful, will broaden the use of tirzepatide to those with manifest or increased risk for CVD, as is the case for GLP-1 receptor agonists [22]

Track Health Care Policy The ever-evolving state health policy landscape will continue to influence how health care organizations make business decisions

GLP-1 is a naturally occurring hormone in our bodies, says Shauna Levy, M.D., director of Bariatric Surgery at Tulane University School of Medicine in TK

These findings reinforce the notion that metabolic dysfunction, and obesity in particular, is not merely a comorbidity but an active modifier of PsA pathophysiology and treatment outcomes